Aardvark Therapeutics Inc (AARD) — Smart Money Tracker (13F, Q2 2026)

AARD ranks #5316 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

AARD is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

72 institutions disclose a position in AARD, but none treat it as a major bet — even Decheng Capital LLC, its most concentrated holder, allocates just 3.1% of its own portfolio to it.

Essential Partners LLC has trimmed its AARD position for two straight quarters, cutting it by $3.2K while still holding $843.0.

AARD reported a net loss of $57.6M in its latest fiscal year.

• Not yet profitable — net loss of $57.6M in the latest fiscal year
• Net income declined year over year, from -$20.6M to -$57.6M
• Operating cash flow was negative, using $54.2M in cash
• Current ratio of 10.61x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.10x equity — within a conventional range